Mangalam Drugs and Organics Ltd. reports Rs 15.5727 crore overdue
Key highlights
- Mangalam Drugs and Organics Ltd. reported Rs 15.5727 crore overdue across two cash-credit accounts as of November 15, 2026.
- Bank of Maharashtra had Rs 9.5119 crore overdue, compared with Rs 6.0608 crore at Bank of Baroda.
- The Bank of Maharashtra default started on October 17, 2025, while the Bank of Baroda default started on October 20, 2025.
- Mangalam Drugs and Organics Ltd. said it was arranging to pay the overdue amount as soon as possible.
powered by IRIS

Mangalam Drugs and Organics Limited reported Rs 15.5727 crore overdue on cash-credit accounts with Bank of Maharashtra and Bank of Baroda as of November 15, 2026, with both defaults continuing for more than 30 days. Mangalam Drugs and Organics Ltd. reported the larger overdue balance of Rs 9.5119 crore at Bank of Maharashtra.
Know Mangalam Drugs and Organics inside out
Results, valuation, peers and who's buying, in one view.
How much does Mangalam Drugs and Organics Ltd. owe banks?
Mangalam Drugs and Organics Ltd. reported total overdue cash-credit borrowings of Rs 15.5727 crore as of November 15, 2026. The amount comprises Rs 9.5119 crore overdue to Bank of Maharashtra and Rs 6.0608 crore overdue to Bank of Baroda, according to the November 16, 2026 disclosure.
The Bank of Maharashtra account accounted for the larger part of the reported overdue amount. Its Rs 9.5119 crore balance was Rs 3.4511 crore higher than the Rs 6.0608 crore reported for Bank of Baroda. Together, the two amounts equal the full overdue sum disclosed in the filing; Mangalam Drugs and Organics Ltd. did not provide an interest-and-principal split.
The disclosure identifies both facilities as cash-credit accounts. The filing describes cash credit as a revolving facility for the purpose of the default rule, but does not state the sanctioned limit, drawing power, interest rate, security, repayment schedule or total outstanding balance for either account.
Which Mangalam Drugs and Organics Ltd. bank accounts are in default?
Mangalam Drugs and Organics Ltd. identified one cash-credit account with Bank of Maharashtra and one with Bank of Baroda as being in default beyond 30 days. The Bank of Maharashtra account number listed was 60383561246, while the Bank of Baroda account number listed was 04170500000243.
For Bank of Maharashtra, Mangalam Drugs and Organics Ltd. reported Rs 9.5119 crore overdue as of November 15, 2026, and gave October 17, 2025, as the date on which the default started. For Bank of Baroda, Mangalam Drugs and Organics Ltd. reported Rs 6.0608 crore overdue on the same date and gave October 20, 2025, as the default start date.
The Bank of Maharashtra default started three days before the Bank of Baroda default. The November 16, 2026 filing characterises both as loan-obligation defaults and does not identify another lender, account or borrowing facility in this communication.
Why did Mangalam Drugs and Organics Ltd. make this disclosure?
Mangalam Drugs and Organics Ltd. made the disclosure under Regulation 30 and Part A of Schedule III of the Securities and Exchange Board of India, or SEBI, Listing Obligations and Disclosure Requirements Regulations, 2015. The November 16, 2026 filing says a listed entity must disclose non-payment of interest or principal when debt has become due and payable.
The filing also sets out the regulation’s treatment of revolving facilities such as cash credit. Under the explanation quoted by Mangalam Drugs and Organics Ltd., a revolving facility is considered in default when its outstanding balance remains continuously above the sanctioned limit or drawing power, whichever is lower, for more than 30 days.
Mangalam Drugs and Organics Ltd. stated that its obligations to Bank of Maharashtra and Bank of Baroda had been in default for a period exceeding 30 days. The report was described as a subsequent intimation, rather than an initial notification, and the accompanying letter refers to an earlier Mangalam Drugs and Organics Ltd. letter dated February 16, 2026.
The November 16, 2026 disclosure does not quantify the overdue balance when the February 16, 2026 letter was issued. The filing therefore provides no source-backed comparison showing whether the Rs 15.5727 crore aggregate overdue amount on November 15, 2026 was higher, lower or unchanged from the earlier disclosed position.
Got a follow-up? Ask IRIS
What has Mangalam Drugs and Organics Ltd. said about repayment?
Mangalam Drugs and Organics Ltd. said it was making arrangements to pay the overdue amount as soon as possible. This is the only repayment statement in the November 16, 2026 filing covering the Rs 15.5727 crore overdue aggregate across Bank of Maharashtra and Bank of Baroda.
Mangalam Drugs and Organics Ltd. did not disclose a payment date, phased payment plan, refinancing arrangement, asset sale, additional funding, lender waiver or restructuring proposal. Mangalam Drugs and Organics Ltd. also did not say how much of the Rs 9.5119 crore Bank of Maharashtra amount or the Rs 6.0608 crore Bank of Baroda amount it expected to clear first.
The filing was signed for Mangalam Drugs and Organics Ltd. by Managing Director Govardhan M. Dhoot. The attached November 16, 2026 communication to the company secretary was signed by Chief Financial Officer Jeevan Dalvi and repeated the same two-account overdue data as of November 15, 2026.
What does the November 2026 filing establish about Mangalam Drugs and Organics Ltd.?
The November 2026 filing establishes that Mangalam Drugs and Organics Ltd. had two named cash-credit facilities in defaults lasting more than 30 days, with Rs 15.5727 crore overdue as of November 15, 2026. Bank of Maharashtra represented the larger disclosed exposure at Rs 9.5119 crore, compared with Rs 6.0608 crore at Bank of Baroda.
It also establishes October 17, 2025, as the default-start date for Bank of Maharashtra and October 20, 2025, for Bank of Baroda. The three-day difference in the start dates is the direct timing comparison between the two facilities supplied by Mangalam Drugs and Organics Ltd.
The filing does not establish Mangalam Drugs and Organics Ltd.'s total bank debt, cash position, operating performance, collateral, lender actions or whether either facility was regularised after November 15, 2026. Those matters are not addressed in the two-page disclosure, so no conclusion on them can be drawn from this announcement alone.
Conclusion
Mangalam Drugs and Organics Ltd. disclosed Rs 15.5727 crore in overdue cash-credit obligations across two banks, with both accounts meeting the stated threshold of defaults lasting more than 30 days. The reported sum was concentrated in the Bank of Maharashtra account, where Rs 9.5119 crore was overdue, compared with Rs 6.0608 crore at Bank of Baroda.
The next item to watch is whether Mangalam Drugs and Organics Ltd. follows through on its stated arrangements to pay the overdue amounts as soon as possible. The filing provides no payment timetable after November 15, 2026, while its reference to the February 16, 2026 letter indicates that Mangalam Drugs and Organics Ltd. had previously notified the market about the defaults.


